Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1739041
Totally Implantable Venous Access Device (Chemoport) in Oncology: Study of 168 Polyurethane Chemoport Catheter System
Funding Nil.![](https://www.thieme-connect.de/media/10.1055-s-00049561/202104/lookinside/thumbnails/10.1055_s-0041-1739041-1.jpg)
Abstract
Background Chemoport (totally implantable venous access device) and its catheter system are used to administer long-term chemotherapy in cancer patients. The objective of this study was to analyze the complications associated with chemoport insertion in various cancer patients.
Material and Methods A total number of 168 chemoports along with polyurethane catheters were inserted in various cancer patients over a period of 3 years. 9.6 F polyurethane catheters were put by a team of surgical oncologists in operation theater under general or local anesthesia. Analysis of the complications was done until the chemoport was removed due to any reason.
Results Out of 168 patients, 30 (17.85%) developed complications. Complications included arterial puncture, malposition of the catheter tip, pneumothorax, hematoma, seroma, deep vein thrombosis, fracture of the catheter, a reversal of port, infections, and thrombosis of the catheter. Only a few required premature port and catheter removal.
Conclusion There was a low rate of complications associated with chemoport using a polyurethane type of catheter system. However, infection-related complications were comparatively more common in our series. Chemoport requires expert handling, patient education, strict follow-up, and dedicated teamwork to minimize complications.
Publication History
Article published online:
31 December 2021
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982; 92 (04) 706-712
- 2 Munck A, Malbezin S, Bloch J. et al Follow-up of 452 totally implantable vascular devices in cystic fibrosis patients. Eur Respir J 2004; 23 (03) 430-434
- 3 Davies MG, Feeley TM, Moore DJ, Shanik GD. Home parenteral nutrition using a totally implanted subcutaneous venous access device. Br J Clin Pract 1990; 44 (12) 750
- 4 Biffi R, De Braud F, Orsi F. et al A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001; 92 (05) 1204-1212
- 5 Biffi R, Orsi F, Pozzi S. et al Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20 (05) 935-940
- 6 Nishinari K, Wolosker N, Bernardi CV, Yazbek G. Totally implantable ports connected to valved catheters for chemotherapy: experience from 350 Groshong devices. J Vasc Access 2010; 11: 17-22
- 7 Brown DF, Muirhead MJ, Travis PM, Vire SR, Weller J, Hauer-Jensen M. Mode of chemotherapy does not affect complications with an implantable venous access device. Cancer 1997; 80 (05) 966-972
- 8 Torramadé JR, Cienfuegos JA, Hernández JL. et al The complications of central venous access systems: a study of 218 patients. Eur J Surg 1993; 159 (6-7) 323-327
- 9 Brothers TE, Von LK Moll, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet 1988; 166 (04) 295-301
- 10 Sticca RP, Dewing BD, Harris JD. Outcomes of surgical and radiologic placed implantable central venous access ports. Am J Surg 2009; 198 (06) 829-833
- 11 Ignatov A, Hoffman O, Smith B. et al An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction. Eur J Surg Oncol 2009; 35 (03) 241-246
- 12 Kreis H, Loehberg CR, Lux MP. et al Patients’ attitudes to totally implantable venous access port systems for gynecological or breast malignancies. Eur J Surg Oncol 2007; 33 (01) 39-43